Complex pyobacteriophage, vial of 100 ml

  • Complex pyobacteriophage, vial of 100 ml
Availability:
In Stock
Product Code:
Complex-pyobac-100
$29.00 $24.65

You save $4.35

Not yet rated Write a review

Complex pyobacteriophage, vial of 100 ml

Presentation

20 ml, 100 ml vials Eight 20ml vials in each cardboard package with a package insert. One 100ml vials in each cardboard package with a package insert.

Ingredients

1 ml of the drug contains the active substance:
  • sterile filtrate of phage lysates of Staphylococcus, Enterococcus, Strep-tococcus, Pseudomonas aeruginosa, Klebsiella pneumoniae, Klebsiella oxytoca, enteropathogenic Escherichia coli, Proteus vulgaris, P.mirabilis - 1 ml.
Excipients: 
  • preservative - 8-hydroxyquinoline sulfate monohydrate - 0.0001 g/ml (estimated content); or
  • 8-hydroxyquinoline sulfate monohydrate - 0.0001 g/ml (equal to 8-hydroxyquinoline sulfate, estimated content).

Indications

  • diseases of the ear, nose, throat, respiratory tract and lungs - inflammation of the sinuses, middle ear, tonsillitis, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleurisy;
  • surgical infections - festering wounds, burns, abscesses, cellulitis, boils, carbuncles, hidradenitis, felon, perirectitis, mastitis, bursitis, osteomyelitis;
  • urogenital infections - urethritis, cystitis, pyelonephritis, colpitis, endometritis, salpingo-oophoritis;
  • post-traumatic conjunctivitis, keratoconjunctivitis, purulent corneal ulcers and iridocyclitis;
  • enteric infections - gastroenterocolitis, cholecystitis, dysbiosis;
  • Generalized septic diseases;
  • purulent inflammatory diseases of newborns - omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, sepsis, etc.;
  • other diseases caused by staphylococci, streptococci, enterococci, Proteus, Klebsiella pneumoniae and klebsiella oxytoca, Pseudomonas aeruginosa and Escherichia coli.
  • For the prevention purposes the drug is use for the treatment of operational and newly infected wounds, for the prevention of hospital-acquired infections on epidemic indications.
  • An important condition for the effective phage therapy is a preliminary determination of the phage sensitivity of the pathogen.

Share

Write a review